Compare Koninklijke Philips NV (PHG) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs 22nd Century Group Inc — how do they compare? Koninklijke Philips NV trades at $24.22 (market cap $23.52B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Koninklijke Philips NV is far larger — about 37833.6× 22nd Century Group Inc's market cap, and Koninklijke Philips NV pays a 4.17% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and 22nd Century Group Inc for 32 Days on average.
| PHG | XXII | |
|---|---|---|
Market Cap | $23.52B | $621.67K |
Volume | 1,635,069 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $32.91 | $483.00 |
52-Week Low | $23.81 | $0.80 |
Typical Hold Time | 84 Days | 32 Days |
Enterprise Value | $29.87B | -$3.69M |
Dividend Yield | 4.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.225, up 0.56% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent news highlights Philips' innovation in healthcare technology including new product launches and strategic partnerships.
While valuation appears reasonable with P/E of 18.94 and EV/EBITDA of 8.86, the stock faces headwinds from bearish technical indicators and mixed analyst sentiment. Investment opportunity lies in continued earnings momentum and healthcare technology leadership, balanced against competitive pressures and execution risks in a challenging market environment.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
